Abstract 110P
Background
Conversion therapy is an important treatment for patients with initial unresectable metastatic colorectal cancer(mCRC) to achieve radical resection. Circulating tumor cells (CTC) are one of the important liquid biopsy methods. There is no study to explore their clinical value in predicting the efficacy. The aim of this study is to explore the value of the number and morphology of CTC in predicting the efficacy of conversion therapy in initial unresectable mCRC patients.
Methods
This study prospectively collected eligible patients with initially unresectable mCRC who were initially diagnosed in Zhongshan Hospital from November 2020 to June 2021. At baseline, after treatment, and before and after conversion resection, multi-point blood sampling was performed. CTC detection using ChimeraX ® Platform; Morphological typing is based on the CTC morphological data of 2083 patients with colorectal cancer who underwent CTC detection in Zhongshan Hospital. Cell Profiler is used for cell feature assignment, clustering and typing.
Results
A total of 126 eligible patients with mCRC participated in this study. According to morphology, CTC can be divided into four morphological types: T1-T4. All 126 patients underwent baseline CTC testing, and 103 patients underwent CTC testing after conversion therapy. After conversion therapy, the positive rate and detection number of CTC significantly decreased (85.7% vs 60.2%, 1.71 vs 1.15, P=0.0052); The detection number of T3 and T4 subtypes significantly decreased (T3: 0.87 vs 0.52, P=0.0026, T4: 0.25 vs 0.06, P<0.0001). The objective response rate was significantly correlated with the baseline number of CTCs (69.8% vs 50.8%, P=0.029), but not significantly with the number of CTCs after treatment. The objective response rate of patients with T3T4 dominance was significantly higher than that of patients with T1T2 dominance (67.6% vs 47.1%, P=0.042). The number of CTC was correlated with patient progression free survival, and baseline CTC positive patients had a worse prognosis (P=0.0012).
Conclusions
The number and morphology of CTCs have good therapeutic and prognostic value for patients with initial unresectable mCRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract